Novel eicosanoid and docosanoid mediators: Resolvins, docosatrienes, and neuroprotectins

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 8, Issue 2, 2005, Pages 115-121

  Serhan, Charles N ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Aspirin; Inflammation; Polyunsaturated fatty acids; Resolution

Indexed keywords

ACETYLSALICYLIC ACID; DOCOSAHEXAENOIC ACID; DOCOSATRIENE; ICOSANOID; ICOSAPENTAENOIC ACID; INDOMETACIN; LEUKOTRIENE; LIPOXIN; NEUROPROTECTIN D1; OMEGA 3 FATTY ACID; RESOLVIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; CELL INTERACTION; DRUG ACTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; FATTY ACID METABOLISM; HUMAN; INFLAMMATION; NEUROPROTECTION; NEUTROPHIL CHEMOTAXIS; NONHUMAN; REVIEW;

EID: 14244258691     PISSN: 13631950     EISSN: None     Source Type: Journal    
DOI: 10.1097/00075197-200503000-00003     Document Type: Review

References (38)

1. Burr GO, Burr MM. A new deficiency disease produced by the rigid exclusion of fat from the diet. J Biol Chem 1929; 82:345.
2. Lands WEM. Diets could prevent many diseases. Lipids 2003; 38:317-321.
3. Bazan NG. Supply of n-3 polyunsaturated fatty acids and their significance in the central nervous system. In: Wurtman RJ, Wurtman JJ, editors. Nutrition and the brain. New York: Raven Press; 1990. pp. 1-22.
4. Simopoulos AP, Leaf A, Salem N Jr. Workshop on the essentiality of and recommended dietary intakes for omega-6 and omega-3 fatty acids. J Am Coll Nutr 1999; 18:487-489.
5. Salem N Jr, Litman B, Kim H-Y, Gawrisch K. Mechanisms of action of docosahexaenoic acid in the nervous system. Lipids 2001; 36:945-959.
6. Helgadottir A, Manolescu A, Thorleifsson G, et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet 2004; 36:233-239.
7. Erlinger TP, Platz EA, Rifai N, Helzlsouer KJ. C-reactive protein and the risk of incident colorectal cancer. JAMA 2004; 291:585-590.
8. Nathan C. Points of control in inflammation. Nature 2002; 420:846-852.
9. Van Dyke TE, Serhan CN. Resolution of inflammation: a new paradigm for the pathogenesis of periodontal diseases. J Dent Res 2003; 82:82-90.
10. Serhan CN, Clish CB, Brannon J, et al. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J Exp Med 2000; 192:1197-1204.
11. Serhan CN, Hong S, Gronert K, et al. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter pro-inflammation signals. J Exp Med 2002; 196:1025-1037.
12. Hong S, Gronert K, Devchand P, et al. Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood and glial cells: autacoids in anti-inflammation. J Biol Chem 2003; 278: 14677-14687. This is the first detailed report of the docosatrienes, novel DHA-derived compounds containing conjugated triene structures, and the resolvins, formed de novo from DHA in human blood, glial cells, and also murine brain. These endogenous 17S-series resolvins have actions equivalent to the aspirin-triggered 17R-series resolvins reported in Ref. [11].
13. Marcheselli VL, Hong S, Lukiw WJ, et al. Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. J Biol Chem 2003; 278:43807-43817. This is the first report showing that 10,17-docosatriene and Resolvin D regulate neutrophil infiltration and protect from tissue damage incurred during stroke.
14. Mukherjee PK, Marcheselli VL, Serhan CN, Bazan NG. Neuroprotectin D1: a docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress. Proc Natl Acad Sci USA 2004; 101:8491-8496. First evidence showing the neuroprotective actions of the novel 10,17-docosatriene and introduction of the term neuroprotectin D1.
15. Corey EJ, Shih C, Cashman JR. Docosahexaenoic acid is a strong inhibitor of prostaglandin but not leukotriene biosynthesis. Proc Natl Acad Sci USA 1983; 80:3581-3584.
16. Lee TH, Mencia-Huerta J-M, Shih C, et al. Effects of exogenous arachidonic, eicosapentaenoic, and docosahexaenoic acids on the generation of 5-lipoxygenase pathway products by ionophore-activated human neutrophils. J Clin Invest 1984; 74:1922-1933.
17. Samuelsson B. From studies of biochemical mechanisms to novel biological mediators: prostaglandin endoperoxides, thromboxanes and leukotrienes. In: Les Prix Nobel: Nobel Prizes, Presentations, Biographies and Lectures. Stockholm: Almqvist & Wiksell; 1982. 153-174.
18. Vane JR. Adventures and excursions in bioassay: the stepping stones to prostacyclin. In: Les Prix Nobel: Nobel Prizes, Presentations, Biographies and Lectures. Stockholm: Almqvist & Wiksell; 1982. 181-206.
19. Bergström S. The prostaglandins: from the laboratory to the clinic. In: Les Prix Nobel: Nobel Prizes, Presentations, Biographies and Lectures. Stockholm: Almqvist & Wiksell; 1982. 129-148.
20. Majno G, Joris I. Cells, tissues and disease: principles of general pathology. Cambridge, MA: Blackwell Science; 1996.
21. Levy BD, Clish CB, Schmidt B, et al. Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol 2001; 2:612-619.
22. Serhan CN. Lipoxins and aspirin-triggered 15-epi-lipoxin biosynthesis: an update and role in anti-inflammation and pro-resolution. Prostaglandins Other Lipid Mediat 2002; 68-69:433-455.
23. Gilroy DW, Lawrence T, Perretti M, Rossi AG. Inflammation resolution: new opportunities for drug discovery. Nat Rev Drug Discov 2004; 3:401-416. Authoritative review that addresses whether the process of resolution holds the promise of new targets and potential drug treatment.
24. GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999; 354:447-455.
25. Marchioli R, Barzi F, Bomba E, et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation 2002; 105: 1897-1903.
26. Rosenstein ED, Kushner U, Kramer N, Kazandjian G. Pilot study of dietary fatty acid supplementation in the treatment of adult periodontitis. Prostaglandins Leukot Essent Fatty Acids 2003; 68:213-218.
27. Bazan NG. Supply, uptake, and utilization of docosahexaenoic acid during photoreceptor cell differentiation. Nestle Nutrition Workshop Series 1992; 28:121-133.
28. Hamberg M, Samuelsson B. On the specificity of the oxygenation of unsaturated fatty acids catalyzed by soybean lipoxidase. J Biol Chem 1967; 242:5329-5335.
29. Sawazaki S, Salem N Jr, Kim H-Y. Lipoxygenation of docosahexaenoic acid by the rat pineal body. J Neurochem 1994; 62:2437-2447.
30. 4-neuroprostanes) in vivo from docosahexaenoic acid. Biochemistry 2000; 39:2376-2383.
31. VanRollins M, Baker RC, Sprecher HW, Murphy RC. Oxidation of docosahexaenoic acid by rat liver microsomes. J Biol Chem 1984; 259:5776-5783.
32. Lands WEM. Diets could prevent many diseases. Lipids 2003; 38:317-321.
33. Arita M, Bianchini F, Aliberti J, et al. Novel omega-3 autacoid resolvin E1: receptor identification and anti-inflammatory properties. J Leukoc Biol 2003; 31 (Suppl): Abstract No. 72.
34. Serhan CN, Oliw E. Unorthodox routes to prostanoid formation: new twists in cyclooxygenase-initiated pathways. J Clin Invest 2001; 107: 1481-1489.
35. Serhan CN, Jain A, Marleau S, et al. Reduced inflammation and tissue damage in transgenic rabbits overexpressing 15-lipoxygenase and endogenous anti-inflammatory lipid mediators. J Immunol 2003; 171:6856-6865.
36. Billman GE, Kang JX, Leaf A. Prevention of sudden cardiac death by dietary pure w-3 polyunsaturated fatty acids in dogs. Circulation 1999; 99:2452-2457.
37. Bazan NG, Birkle DL, Reddy TS. Docosahexaenoic acid (22:6, n-3) is metabolized to lipoxygenase reaction products in the retina. Biochem Biophys Res Commun 1984; 125:741-747.
38. Rowley AF, Lloyd-Evans P, Barrow SE, Serhan CN. Lipoxin biosynthesis by trout macrophages involves the formation of epoxide intermediates. Biochemistry 1994; 33:856-863.